Resilience and INCOG BioPharma Announce Collaboration to Expedite Manufacturing of Biological Drug Substance and Drug Product
For Immediate Release
Partnership will support biopharma innovators seeking an integrated solution from drug substance to drug product manufacturing
SAN DIEGO, CA & FISHERS, IN, May 23, 2022– National Resilience, Inc. (Resilience) and INCOG BioPharma Services, Inc. (INCOG) today announced a collaboration to streamline and expand biomanufacturing services for companies delivering existing and new therapies to market.
This collaboration will provide life sciences companies with integrated process development, drug substance, and drug product manufacturing services in a unified solution. Companies entering into an agreement with Resilience, a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, will have access to its expertise in process and analytical development and Good Manufacturing Practices (GMP) manufacturing of drug substance for biologics, vaccines, and nucleic acids. INCOG, a contract development and manufacturing organization (CDMO) specializing in sterile injectables, through a separate agreement will provide Resilience customers with its formulation and fill-finish drug product expertise.
This partnership will support biotech and pharmaceutical innovators seeking an integrated solution and a smooth transition from drug substance to drug product manufacturing, with the added benefit of centralized project management and an aligned approach. Customers who work within this collaboration will save in transition time, receive comprehensive solutions to bring their drug product to patients safely and efficiently, and will benefit from having scale-up activities supported via an integrated clinical to commercial scale manufacturing solution.
“INCOG is a purpose-built CDMO, with a keen focus on delivering a superb customer service experience, while leveraging best-in-class manufacturing assets in our purpose-built facility. By partnering with Resilience and connecting our respective service offerings, we will accelerate our biopharma customers’ ability to get their product into the clinic and into the commercial markets,” said Cory Lewis, CEO and President at INCOG BioPharma Services.
INCOG is nearing completion of its 90,000 square foot facility in Fishers, Indiana, where it will support biopharma companies advancing early-stage clinical therapies as well as commercial-stage manufacturing.
Resilience is building a network of state-of-the-art manufacturing facilities that aim to be digitally enabled, and flexible enough to scale customer projects from small batch pre-clinical to large scale commercial production. The collaboration complements Resilience’s rapidly expanding in-house drug product capabilities and expertise at sites in Mississauga, ON, Marlborough, MA, Research Triangle Park, NC, and Alachua, FL.
Both companies have the capability and capacity to quickly ramp up to deliver solutions for clients looking for a cohesive drug substance and drug product solution.
About INCOG BioPharma Services
Designed to deliver better. Discover the INCOG way.
We designed and built INCOG BioPharma based on decades of experience with a clear purpose: to deliver better CDMO services in the injectable drug product space. The company’s service offering includes filling drug product into vials, syringes, and cartridges. INCOG BioPharma also offers support services to include formulation development, analytical development, stability testing and storage, and final inspection, labeling, packaging, and device assembly. With our dedicated team, best-in-class processes, and state-of-the-art equipment, we deliver meaningful results and stand-out customer experiences. We stand behind our motto, “in it with you,” from the moment we start work on your project. We go above and beyond to understand your requirements, meet your needs, and foster a truly collaborative partnership.
Corporate Development Manager
Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives.
For more information, visit www.Resilience.com and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn.
Head of Communications, Resilience